The companies hope to deliver longitudinal and personalized connected care for OSA. Through this collaboration, healthcare providers who prescribe a ProSomnus RPMO₂ device can view, organize and remotely monitor patient data within the MonitAir platform. The companies hope to facilitate clinical visibility into patient status over multiple nights to support coordination of care.
San Francisco–based ProSomnus designed its FDA-cleared RPMO₂ system to incorporate both precision oral appliance therapy and multi-night physiologic monitoring in a single device.
The RPMO₂ device capabilities include measuring oxygen saturation (SpO₂) and pulse rate. ProSomnus says its device delivers connected, patient-centric, evidence-driven OSA care in the new “Smart Sleep Medicine” era. The company brought in $38 million earlier this year to support this technology.
ProSomnus’ device incorporates a fully embedded oximeter for safe, accurate multi-night OSA monitoring. Encapsulated in an overlay of the maxillary dentition, the oximeter uses the mucosa of the buccal vestibule behind the upper lip as reflective tissue. Data is transmitted to a secure provider portal via a patient smartphone app.
MonitAir delivers an FDA-registered platform that integrates remote physiologic monitoring (RPM), remote therapeutic monitoring (RTM), and chronic care management (CCM) capabilities into a unified workflow. It aggregates data from connected devices and provides tools for data visualization, compliance tracking and communication. The platform supports clinicians in managing patients with sleep-related and respiratory conditions.
Commentary from ProSomnus and MonitAir officials
Len Liptak, CEO of ProSomnus, said:
“Despite well-documented health, quality of life, and economic consequences, OSA remains undertreated due to fundamental limitations in how the condition is measured and managed—including night-to-night variability, reliance on frequency-based metrics that may not fully reflect health risk, and limited connectivity between patients and providers. Our collaboration with MonitAir is designed to address these limitations in OSA care by enabling longitudinal remote monitoring of physiologic data generated by the ProSomnus RPMO₂ OSA device—supporting a more connected, data-driven, and personalized approach to care and helping expand access to treatment.
Dr. Edward Mezerhane, CEO of MonitAir, said:
“Effectively managing Obstructive Sleep Apnea requires continuous, actionable insights, not just a single snapshot in time. By integrating the high-fidelity data from the ProSomnus RPMO₂ OSA device directly into MonitAir’s comprehensive monitoring platform, we are giving clinicians the longitudinal visibility they need. This partnership bridges the critical gap between the patient’s home use and the provider’s clinical decision-making, empowering practices to optimize therapy, track compliance seamlessly, and deliver a higher standard of personalized care.”
